INTRODUCTION {#sec1-1}
============

Periodontitis is a chronic inflammatory disease of supporting tissues of the teeth in response to noxious stimuli whether mechanical, chemical or infectious, resulting in progressive destruction of periodontal apparatus, hence leading to pocket formation, recession or both.\[[@ref1][@ref2][@ref3][@ref4][@ref5]\] The tissue destruction in periodontitis has been attributed to the production of enzymes and reactive oxygen species (ROS) by polymorphonuclear cells and other cells. It has been demonstrated that patients with periodontitis have higher oxidative DNA and lipid damage biomarkers and lower antioxidant (AO) enzymatic activities in saliva than healthy subjects.\[[@ref6]\] There are a variety of defense mechanisms in the body to combat excessive ROS production, and AOs are one among these. AOs are those substances when present at a low concentration compared to those of an oxidizable substrate significantly delays or prevents oxidation of the substrate.\[[@ref7]\] They act at three different levels - prevention, interception, and repair.\[[@ref8]\] Superoxide and hydrogen peroxide are the main oxidative species produced, which are either enzymatically eliminated by preventive AOs, or metal ions are sequestrated, hence preventing Fenton reactions and subsequent hydroxyl radical formation\[[@ref9]\] e.g. -- catalase, glutathione (GSH) peroxidase, 7 S-transferase. Interception involves scavenging/chain breaking AOs which inhibit chain initiation, chain propagation and also lipid peroxidation e.g. -- lipophilic substances such as ubiquinol, Vitamin A, Vitamin E, carotenoids and hydrophilic substances like uric acid, ascorbic acid, albumin, and bilirubin. At repair level various AOs function by repairing the damaged and reconstituting membranes. These include DNA repair enzymes, protease, transferase, and lipase.

When the level of ROS increases intracellularly, the cellular AO defenses are insufficient to maintain these harmful molecules, this condition is generally referred to as "oxidative stress." The concept of "oxidative stress" dates back to 1986 and was elaborated as the relation between free radicals and disease.\[[@ref10]\] GSH is a ubiquitous tripeptide made from the combination of three amino acids, that is, cysteine, glutamate, and glycine. It is a low molecular weight thiol (up to 5--10 mM) present in the cell and existing in two forms which are oxidized glutathione (GSSG) and reduced GSH forms.\[[@ref11]\] Out of the total GSH present in the body, the reduced GSH constitutes about 90%, and GSSG is 10%. For survival of cell, it is imperative to maintain optimal GSH: GSSG ratios. Oxidative damage results when the there is a deficiency of reduced GSH in the cell, which puts it at risk for oxidative damage.\[[@ref11]\] Reduced GSH plays three major functions in the body.\[[@ref12]\]

Anti-oxidant function \[[Figure 1](#F1){ref-type="fig"}\]Detoxification functionImmune function.

![Schematic representation of the biochemical interactions between neutrophil superoxide and glutathione](EJD-9-415-g001){#F1}

The purpose of this study is to compare the levels of GSH, both oxidized and reduced forms in patients with and without chronic periodontitis in gingival crevicular fluid (GCF).

MATERIALS AND METHODS {#sec1-2}
=====================

Study groups and design {#sec2-1}
-----------------------

This study was a 6 months randomized case--control study, which was conducted at the Department of Periodontology. An approval for the study was obtained from the ethical committee, and written informed consent was obtained before enrolling the subjects for the study. The study enrolled 40 patients, which included patients with chronic periodontitis *n* = 20 (test group) and patients without chronic periodontitis *n* = 20 (control group). Subjects with no relevant medical history of tobacco usage were enrolled for the study. Subjects in the test group were selected on the basis of clinical criteria of having at least two nonadjacent sites per quadrant with probing pocket depths ≥5 mm, along with bleeding on probing and demonstrable radiographic bone loss. Control patients did not show evidence of attachment loss or probing pocket depths ≥3 mm and bleeding scores were below 10%. The subjects with a history of taking vitamin supplements, anti-inflammatory or antibiotic medication in the preceding 3 months and pregnant ladies and patient with special dietary needs were not included in the study. The study was started in January 2013 and ended in July 2014. After enrollment, baseline GCF samples were collected, before recording clinical measures which included Silness and Loe plaque index, Loe and Silness gingival index, Muhlemann and Son sulcus bleeding index and probing pocket depth. After data collection, chronic periodontitis patients (test group) underwent scaling and root planing and oral hygiene instruction which included brushing technique, dental flossing were reinforced at baseline. Patient without chronic periodontitis (control group) received only oral hygiene instructions. Subjects were then recalled at 1-month, 3 months and 6 months posttherapy for recording clinical and biochemical parameters.

Gingival crevicular fluid collection and glutathione estimation {#sec2-2}
---------------------------------------------------------------

GCF samples were collected from mesiobuccal/distolingual sites on any teeth in the maxillary quadrant (test and control group) using microcapillary pipettes. GCF samples were then immediately transferred to top sealed cuvettes to prevent oxidation of AOs present in it. Levels of reduced and GSSG were analyzed using \"beutler\" spectrophotometric test.\[[@ref13]\]

Data analysis {#sec2-3}
-------------

All the results of this study were obtained by comparing intragroup and intergroup parameters, at various designated phases at baseline, 1^st^ month, 3^rd^ month and 6^th^ month for test over control groups using paired Student\'s *t*-test using software Computer software SPSS version 20 (IBM SPSS Inc, Chicago, IL, USA).

RESULTS {#sec1-3}
=======

Clinical data {#sec2-4}
-------------

The nonsurgical periodontal therapy provided to the test group resulted in observed reductions of whole mouth mean plaque scores (*P* \< 0.001), mean gingival scores, and mean sulcus bleeding index scores in the group (*P* \< 0.001) Which in turn showed reduced inflammation as compared to control group \[Tables [1](#T1){ref-type="table"}--[6](#T6){ref-type="table"}\].

###### 

Intra-group comparison of mean plaque scores and SD in test group
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###### 

Intra-group comparison of mean gingival index scores and SD in test group
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###### 

Intragroup comparison of mean SBI scores and SD in test group
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###### 

Intragroup comparison of mean plaque scores and SD in control group
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###### 

Intragroup comparison of mean gingival index scores and SD in control group
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###### 

Intragroup comparison of mean sulcus bleeding index score and SD in control group
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Glutathione levels in gingival crevicular fluid {#sec2-5}
-----------------------------------------------

In all groups, mean reduced GSH and GSSG levels were detected in the millimolar range (range: 0.30--5.14 mM \[[Table 7](#T7){ref-type="table"}\]). Lower levels of GSH and GSSG concentrations were reported in the GCF from chronic periodontitis patients before and after treatment, compared with those detected in nonchronic periodontitis subjects (control group) \[[Table 8](#T8){ref-type="table"}\].

###### 

Mean ratio of reduced glutathione and oxidized glutathione and SD in test group
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###### 

Intergroup comparison between various parameters used in study between test and control group

![](EJD-9-415-g009)

Comparative analysis of difference in mean GSH and GSSG value for test group was done at different time intervals, namely, baseline -- 1-month, baseline - 3 months, baseline - 6 months, 1--3 months and 1--6 months. The differences were observed to be statistically significant (*P* \< 0.001) at a confidence interval of 95%, but statistically nonsignificant at the 3--6 months interval \[Tables [9](#T9){ref-type="table"} and [10](#T10){ref-type="table"}\]. Comparison of mean GSH and GSSG score with a standard deviation between test and control group is depicted \[Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}\] GSH and GSSG value for control group were depicted at different time intervals, namely, baseline -- 1 month, baseline - 3 months, baseline - 6 months, 1--3 months and 1--6 months in Tables [11](#T11){ref-type="table"} and [12](#T12){ref-type="table"}.

###### 

Intragroup comparison of mean reduced glutathione level and SD in test group
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###### 

Intragroup comparison of mean oxidized glutathione level and SD in test group

![](EJD-9-415-g011)

![Reduced glutathione levels at different time intervals for test and control groups](EJD-9-415-g012){#F2}

![Oxidized glutathione levels at different time intervals for test and control groups](EJD-9-415-g013){#F3}

###### 

Intragroup comparison of mean reduced glutathione level and SD in control group
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###### 

Intragroup comparison of mean oxidized glutathione level and SD in control group

![](EJD-9-415-g015)

Ratio of reduced GSH and GSSG for test group at different time interval during the study was reported to be statistically significant (*P* \< 0.001) at confidence interval of 95% at baseline -- 1-month, baseline - 3 months, baseline - 6 months, 1--3 months, 1--6 months \[[Table 7](#T7){ref-type="table"}\]. Comparison of the mean ratio of reduced and oxidized GSH (GSH: GSSG) score with a standard deviation between test and control group is depicted in [Figure 4](#F4){ref-type="fig"}. The GSH and GSSG ratio values for control group were shown in [Table 13](#T13){ref-type="table"}. This improvement in the GSH: GSSG ratio after treatment was as a result of an increase in levels of reduced GSH and a reduction in levels of oxidized GSH.

![Ratio of reduced to oxidized glutathione levels at different time intervals for test and control groups](EJD-9-415-g016){#F4}

###### 

Intragroup comparison of mean ratio of reduced glutathione and oxidized glutathione and SD in control group

![](EJD-9-415-g017)

DISCUSSION {#sec1-4}
==========

The present data confirm the study conducted by Chapple *et al.*, 2002 suggesting that a millimolar concentration of GSH was present in GCF, which decreases during periodontitis. The reduction in GSH levels is suggestive of its protective role for vital cells and tissue structures from host-derived free radicals. Due to the conversion of GSH to GSSG, there is a reduction in GSH levels at inflamed tissue sites as also seen in this study. Similarly, the reduced GSH: GSSG ratio at baseline was due to reduced levels of GSH as well as increased accumulation of GSSG. These results were consistent with findings reported in earlier studies demonstrating a reduction in total antioxidant capacity of saliva in patients with chronic periodontitis along with reduced levels of GSH.\[[@ref15][@ref16][@ref17]\]

In this study, a significant increase in GSH levels along with improvement in GSH: GSSG ratio at 1-month was observed following nonsurgical periodontal therapy viz., scaling and root planing, which is consistent with the observations made by several others studies.\[[@ref18][@ref19][@ref20]\] These results were suggestive of an improvement in AO status and reduction in oxidative stress following nonsurgical periodontal therapy. Other possibilities for the improvement seen following nonsurgical therapy is the reduction in proteolytic activity of microorganisms and also reductions in inflammation posttherapy, thereby lowering levels of oxidants in GCF, both exogenously and endogenously. The improvement was seen in GSH: GSSG ratio at 3 months is due to relatively long duration taken by subgingival microflora to reestablish, hence their reduced activity.\[[@ref2]\]

The preliminary findings of studies stated that millimolar concentrations of GSH is present in GCF gets significantly reduced in chronic periodontitis patients.\[[@ref14][@ref19]\] In addition, this study demonstrated that successful, nonsurgical periodontal therapy does restore the redox balance (GSH: GSSG) till 3 months, but at 6 months no significant improvement in either GSH or GSH: GSSG ratio was noted. Thus after 3 months thorough oral hygiene practice is not self-sufficient for restoring the GSH levels and GSH: GSSG ratio to health, this implies that there is a reduced potential of periodontal tissues against ROS activity in chronic periodontitis patients, even after successful nonsurgical therapy. Such findings have opened up the potential of using pharmacological agents to elevate buffering capacity within tissues by elevating GSH levels, e.g. use of the GSH promoting drug N-acetyl cysteine. This pharmacological approach is currently under investigation in the management of rheumatoid arthritis.\[[@ref20][@ref21]\] Anti-inflammatory tissue redox state can be created by supplementing the individuals with micronutrients for elevating GSH concentrations.\[[@ref22]\] For various chronic inflammatory diseases that are associated with redox imbalance, AO supplementation is actively pursued as a preventive and therapeutic measure.

Limitations {#sec2-6}
-----------

Duration of the study, the reliability of the spectroscopic method used for GSH estimation and method of GCF collection. This study opens up scope for various future studies dealing with the role of GSH as biological diagnostic disease marker, AO, detoxifier, and immune modulator. Long-term studies can be undertaken to evaluate the efficacy of novel therapeutic approaches for improving the buffering capacity within periodontal tissues by elevating the GSH levels.

CONCLUSIONS {#sec1-5}
===========

The study concluded that at baseline due to prevailing oxidative stress the levels of reduced GSH were reduced in patients with chronic periodontitis. Following nonsurgical therapy the levels of GSH were improved at 1-month and 3 months. At 6 months recall following nonsurgical therapy, an adjunctive use of micronutritional supplements to boost AO concentration in tissues by preserving GSH or by elevating its level at the inflamed sites is recommended.

Financial support and sponsorship {#sec2-7}
---------------------------------

Nil.

Conflicts of interest {#sec2-8}
---------------------

There are no conflicts of interest.
